Stocks in Action USA: Insmed, D.R. Horton, Oklo
Reading Time: 4 minutes
Insmed (INSM) – Revenue Explosion from New Drug "Brinsupri": Biotech Specialist on the Cusp of a Decisive Year 2026! Shares of biopharma company Insmed surged over 10% in response to the preliminary business figures for 2025, signaling successful commercial scaling. The company reported a massive revenue increase of 67% to USD 606.4 million ahead of the J.P. Morgan Healthcare Conference, with the launch of the new drug BRINSUPRI exceeding all expectations: In its first full sales quarter alone, the drug generated approximately USD 144.6 million,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
